How Much Did Alzheon Raise?
Funding & Key Investors

Alzheon, a clinical-stage biopharmaceutical firm, has successfully secured a significant capital injection, bringing its total funding to $182M. This latest financing round, which contributed $100M to the company's balance sheet, underscores the market's confidence in its proprietary oral anti-amyloid therapeutic platform. As the company advances through critical late-stage clinical trials, this influx of investment serves as a vital catalyst for its ongoing research and development initiatives.

The trajectory of Alzheon reflects a disciplined approach to capital acquisition, moving from early-stage private equity and Series A rounds in 2013 and 2015 to more substantial Series D and E financing. This progression highlights the company's ability to hit key milestones in the complex landscape of Alzheimer's disease drug development, positioning it as a high-potential player in the neurodegenerative therapeutics sector.